Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.14 Premarket
DECN to Finance 2Q 2020 Roll Out of its GenViro! Covid-19 "Rapid" Kits Using Non-Dilutive Debt Financing Totaling $13 Million Acquired in Near 0% Rate Environment.
The consensus is that broad based testing is needed.
Asymptomatic testing is needed.
Testing and more testing.
Coronavirus Outbreaks Could Become Seasonal Woe, Some Researchers Find
https://www.wsj.com/articles/coronavirus-outbreaks-could-become-seasonal-woe-some-researchers-find-11584955802?mod=djemHL_t
Huge volume trading here, not investorshub money.
Per Fridays' PR, DECN has secured $13 million in financing.
That's a bit of money and don't think that comes very easy.
I believe big things are in play here.
Excellent week for DECN, much progress being made.
Crazy volume this week and even impressive volume today for a Friday.
Strong close, looks like Monday will be a strong open.
Great job Mr. Berman securing financing!
Looking forward to reading more in next PR's.
All the pieces are falling into place.
Thank you!
The differentiating technology that allows DECN to make a superior Coronavirus test is their impedance technology:
Please read:
https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full
This is highly regarded publication with a significant impact factor which has been peer reviewed by industry scientists. The technology is sound and works!
Take a look at the date a publication. Over the years the technology has been perfected by DECN and is now being tuned for CV screening.
Yes, things cost money. But DECN is moving forward securing financing needs, see news from today.
DECN has an existing manufacturing, distribution, and know-how to get things done. They will leverage their background and scale to meet the massive demand for CV screening.
This company has been around for a long time and they aren’t new at diagnostics. Their other products can readily be purchase. Please see here:
https://www.dropbox.com/s/asmk4k7fjhxe3d0/IMG_0804.jpeg?dl=0
https://www.dropbox.com/s/2911s3ilay7kxw2/IMG_0805.jpeg?dl=0
https://www.dropbox.com/s/z7xusnwz65n0omw/IMG_0806.jpeg?dl=0
You can buy their products right now on Amazon and others, just like I did.
It’s not like is out of the ordinary business for DECN, again they are a diagnostics company moving into CV screening - diagnostics! It’s logical and smart! This is a real company, with real products, with great management. I see great things ahead. Good work Mr. Berman and DECN!
This is anti dilutive!
DECN to Finance 2Q 2020 Roll Out of its GenViro! Covid-19 "Rapid" Kits Using Non-Dilutive Debt Financing Totaling $13 Million Acquired in Near 0% Rate Environment
https://www.accesswire.com/581701/DECN-to-Finance-2Q-2020-Roll-Out-of-its-GenViro-Covid-19-Rapid-Kits-Using-Non-Dilutive-Debt-Financing-Totaling-13-Million-Acquired-in-Near-0-Rate-Environment
The only thing that is bad is you. Go away, you're a horrible person.
Johnny C, you're a daddy's boy and convicted felon. Time to grow up, and get a life instead of sitting around a forum. Day in and day out with you jeez. Bye bye.
You've always been a questionable character but that fact that you sold your daddy's shares and still hang around, you're down right despicable. Get a life!
Incredible close, huge buying right now.
From this morning press release:
Mr. Berman concluded, "I have been in and around the in-vitro diagnostics business for over 40 years, and never before in all of that time, have I witnessed a policy like this. This latest guidance from the FDA shaves months from our product development process, and we all shall reap these benefits. Tomorrow we will discuss our new plans going forward now that we will shortly be a two product coronavirus diagnostics company."
Excellent day today, looking forward to tomorrow.
Good day today. Looking forward to hearing more tomorrow. Expecting more information on second product and the second forecast for institutional sales.
Mr. Berman concluded, "I have been in and around the in-vitro diagnostics business for over 40 years, and never before in all of that time, have I witnessed a policy like this. This latest guidance from the FDA shaves months from our product development process, and we all shall reap these benefits. Tomorrow we will discuss our new plans going forward now that we will shortly be a two product coronavirus diagnostics company."
Decision Diagnostics at its core is a diagnostics company. The technology that gives them the competitive advantage has been perfected and refined over the years. Their impedance technology is the golden ticket here. I encourage all to read, very interesting!
https://pr.report/HSwOa7WG
The market for Coronavirus and diagnostics is tremendous and people need CV screening! Glad there are people like Mr. Berman and companies like Decision Diagnostics.
Nice to see the FDA cutting some of the red tape, making it easier for companies like DECN to bring product to market.
An excerpt from today's PR:
"GenViro!™ has been validated at the company's R&D center in Daegu, Korea"
Very impressive.
The revised forecast of 525 million units does not include figures for sale to hospitals, which is also a major source of revenue.
Expect a second forecast in the near term.
Pretty huge news here. See below from this morning's press release.
"Today, in this second of four updates about our GenViro™ Swift" kit for the testing of COVID-19, we will focus on our expected roll-out. We are happy to inform all interested parties that we have raised our 12-month forecast to 525 million kits."
Mr. Berman continued, "Over the weekend, and after receiving a plan from our technical and R&D director, we decided to take the next step with GenViro™and further refine its use for hospitals. While we have not yet forecast sales to hospitals, and while most of the lesser but competitive products are directed toward hospital uses, we nonetheless believe that hospitals will be a large future source of revenues. When we complete this round of information releases, our fourth release will include a hospital forecast.
The fourth press release will include a second forecast in addition to the current 525 million unit forecast.
Big Buyer
Nothing worse than a cry baby.
Per previous press releases, I’m expecting new updates soon.
I highly recommend everyone read this:
https://www.frontiersin.org/articles/10.3389/...00940/full
DECN is using their novel impedance measurement technology to screen for Coronavirus. This technology has already been perfected for the use in their TBG product!
Their tests will yield more accurate results, will have quicker turn around times, and are cheaper.
Company has already presented to the White House and has retrained FDA counsel who is in the process of securing expected emergency waiver.
See here:
http://www.pharmatechsolutions.co/assets/inse...ro!_PP.pdf
Good work Mr. Berman and DECN.
I highly recommend everyone read this:
https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full
DECN is using their novel impedance measurement technology to screen for Coronavirus. This technology has already been perfected for the use in their TBG product!
Their tests will yield more accurate results, will have quicker turn around times, and are cheaper.
Company has already presented to the White House and has retrained FDA counsel who is in the process of securing expected emergency waiver.
See here:
http://www.pharmatechsolutions.co/assets/inserts/20200313_GenViro!_PP.pdf
Good work Mr. Berman and DECN.
Take a look at this:
https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full
Electrical engineering is such an interesting subject!
DECN's test will yield quicker turn around times, are cheaper, and are more accurate.
Good job Mr. Berman and DECN.
"What makes the testing for the Coronavirus possible, and the GenUltimate TBG special, is the company's Impedance measurement technology."
Please read:
https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full
DECN is a diagnostics company with manufacturing in S. Korea.
Unfortunate but DECN is in a unique position right now.
DECN tests will be cheaper, have quicker turn around time, and yield better results.
The White House has already seen DECN's presentation:
http://www.pharmatechsolutions.co/assets/inserts/20200313_GenViro!_PP.pdf
With updates coming in the near term, this stock is going to rock. Hope people loaded on that relative light volume pull back Friday.
Excited for the next couple of days. A lot of moving parts going on now and I’m enthusiastic to hear what Mr. Berman and DECN are doing. FDA, big box, manufacturing, partnering, etc. DECN’s technologies will save a lot of lives. Cheaper and quicker turn around time.
Presentation presented to the White House:
http://www.pharmatechsolutions.co/assets/inserts/20200313_GenViro!_PP.pdf
Test test testing! Mr. Berman, your technology will put a lot of minds at ease with your affordable test kits.
Very happy shareholder here!
Very impressive! Thank you for sharing! Mr. Berman has been hard at work. Looks like great things are ahead!
I have to disagree with you.
I thought DECN's attorney's argument had a lot of conviction, was extremely clear, and was easy to follow. While, I do think the judges pressed him a bit, DECN's attorney did a very fine job at answering the questions. We are potentially talking about a lot of money being awarded to DECN, the judges have every right to ask tough questions. Maybe playing devil's advocate a bit? I like how we did.
I thought Lifescan's attorney was a bit weak to be honest. His voice did not convey the conviction that DECN's attorney's voice did, and relied on the court's previous rulings to demonstrate his point. Seemed like he had to stand on the shoulders of other people's work to make his point. Not saying that it's bad, but seemed like a weaker argument.
I think DECN has some money coming to them and that's why the judges pressed DECN's attorney so much. They wanted to make sure before they make a ruling in DECN's favor which involves a lot money.
Good luck everyone.
LifeScan Enters into Agreement with Sanvita Medical to Market and Distribute Continuous Glucose Monitoring (CGM) Devices
https://www.prnewswire.com/news-releases/lifescan-enters-into-agreement-with-sanvita-medical-to-market-and-distribute-continuous-glucose-monitoring-cgm-devices-300853566.html
I'm happy to see this. It shows that Lifescan is willing to work with outsiders. I'm under the impression the the old Lifescan under JNJ was very much only about using in house technologies. This shows Platinum's Lifescan is more open minded with working with outside partners.
DECN's Appeal Nearing Oral Arguments in its Patent Battle with Johnson & Johnson Over the Unjust Ruling in the Nevada Lower Court
Tuesday, May 7, 2019 8:55 AM
Appeals Court Set to Hear and Then Decide DECN's Seminal Legal Question at Issue in Long Simmering Patent Battle with Johnson & Johnson and its Successor
LOS ANGELES, CA / ACCESSWIRE / May 7, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ("Dragonfly") highly precise diabetes testing system, ready for clinical trials.
In October 2018, DECN found itself on the wrong side of an inaccurate and unfair ruling by the Nevada Federal District Court in its long running patent battle with industry giant Johnson & Johnson (J&J). Specifically, the Court modified the questions at issue long after the conclusion of the briefings and oral arguments. Rather than directing his ruling to the "equivalent" (which in DECN's case is the J&J/LifeScan system), the Court instead directed its ruling to the system claimed in DECN's patents. More specifically, the Court misrepresented DECN's principal arguments with its ruling by mistakenly comparing DECN's patented system to itself and ignoring J&J's infringing system and the basis for DECN's lawsuit.
DECN immediately appealed this lower court ruling to the United States Court of Appeals for the Federal Circuit (the patent court). Briefings were completed and some 10 days ago the Federal Circuit court asked both sides to provide ''black-out'' dates so that the court could set the date for the court ordered Mediation and the oral arguments. Dates from the Federal Circuit court are expected shortly and are tracking presently for events to occur in mid-June 2019.
Keith Berman, CEO of DECN, commented, ''While we were obviously disappointed by the lower court's ruling, where upon analysis it appears that the trial judge ignored the entirety of DECN's principal arguments and handed J&J a victory. We concluded that the judge was wrong, and J&J's foot dragging indicates to us that they probably think so too.
Mr. Berman continued, ''Although egregious in itself, this Court also short circuited DECN's right to bring a false advertising claim in our original action. J&J's Chairman, who had extensively discussed the workings of J&J's system in public forums and in the media, represented that J&J's system operated in a manner that if he were taken at his word, infringed on DECN's patented system; a clear confession of guilt to patent infringement. However, in their lawsuit defense, J&J argued that their Chairman ''misspoke.'' If this is true, then J&J's Chairman misspoke numerous times over an extended period, and was never corrected by his staff. J&J cannot have it both ways. Either their OneTouch Ultra system, subsequently sold to private equity firm Platinum Equity, is the equivalent to ours, which we strongly believe to be true, or the J&J Chairman's public statements constitute false advertising of a product that J&J sold over 30 million boxes of annually for the 6-year look back period of time.''
In the upcoming arguments in front of a 3-judge Appeal panel, DECN will argue the highly erroneous nature of the Court's unacceptably misstated "tangential exception" question. That being said, the act of comparing DECN's system to itself was not the worst part of the trial judge's ruling. When the trial judge ordered the court clerk to dismiss the lawsuit with prejudice, that act also foreclosed DECN's ability to bring a false advertising claim against J&J in this case. The record in this lawsuit strongly suggests that J&J engaged in false advertising on the part of J&J's Chairman who made numerous public statements to audiences that had the effect of describing in detail DECN's patented system.
Mr. Berman concluded, ''We firmly believe that the Federal Circuit will easily follow our arguments, which were made in pleadings and then will be made again in the upcoming oral arguments. The company plans an additional updates as soon as the court sets the date for the oral arguments. Once dates are set, we can more clearly handicap the path and schedule to an Appeals Court ruling in this matter. While it may appear that little has happened in this matter, the opposite is true. The company does not expect this case to go to trial. J&J has sold their Lifescan, Inc. division and must, at this point view this patent matter as something hanging out there that requires resolution. ''
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $12 billion at-home testing market.
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of May 6, 2019, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
info@decisiondiagnostics.com
www.genultimate.com
www.petsureteststrips.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.